FR2945944A1 - Use of as cosmetic agent of probiotic microorganism in particular of Lactobacillus and Bifidobacterium species genus, for treating scalp disorders e.g. dandruff condition, pruritis or seborrhoeic dermatitis - Google Patents

Abstract

For preventing and/or treating scalp disorders, at least one probiotic microorganism in particular of the Lactobacillusand/or Bifidobacterium speciesgenus, of its fraction and/or metabolite, as cosmetic agent is used. Independent claims are included for following: 1) a cosmetic and/or dermatological composition for preventing scalp disorders comprising effective amount of probiotic microorganism, in particular of the Lactobacillusand/or Bifidobacterium speciesgenus, in combination with an effective amount of at least one active agent selected from antidandruff active agent and/or hydrating active agent; 2) cosmetic process for preventing and/or treating dandruff condition of scalp involving administering a first cosmetic active agent over a first and second consecutive periods of time, where the periods of time together forming a sequence, and at least second cosmetic active agent, topically over a single period of time selected from the first and second periods of time, where the first and second cosmetic active agents being formulated in separate compositions, the first cosmetic active agent being selected from probiotic microorganisms, and the second cosmetic active agent being selected from antidandruff active agents; and 3) cosmetic assembly comprising at least first and a second cosmetic composition, where the first composition containing at least an effective amount of at least first cosmetic active agent, the first cosmetic active agent being Lactobacillus paracasei, and the second composition containing a second cosmetic active agent selected from antidandruff active agents and being administered topically. ACTIVITY : Dermatological; Antipruritic; Antiseborrheic. Test details described, but no results given. MECHANISM OF ACTION : None given.

Description

The present invention aims to propose a new cosmetic process for the prevention and / or treatment of a dandruff condition of the scalp. Also, the present invention relates to an assembly, or kit, suitable for a method of the invention. The scalp is an epidermis with continual renewal, like the rest of the cutaneous tissue, and rich in sebaceous glands. Normally, the scalp is renewed by removing the superficial cells of the skin, insensitively and not visible. However, an excessive renewal of the cells of the stratum corneum of the scalp, for various reasons, can lead to the formation of clusters of large, thick cells, visible to the naked eye, called dandruff. Different factors can promote the appearance of dandruff. For example, one can mention the stress, the winter period, an excess of sebum, a defect of hydration or the colonization of the skin or the hair follicles by yeasts of the type Malassezia sp .. These factors have, in particular, for character common cause and / or promote an inflammatory skin condition. Such inflammation enhances the appearance or even increases the presence of dandruff. In particular, yeasts of Malassezia sp. which can represent approximately 45% of the normal commensal flora on the surface of the scalp in subjects without film, represents 75% of the flora in case of dandruff, even 85% in case of associated seborrheic dermatitis. The imbalance of the ecoflora of the scalp is a factor favoring or even reinforcing the presence of dandruff. These dandruff conditions of the scalp result in an alteration of the barrier function of the epidermis. Moreover, these states can generate itching or pruritus sensations, leading to scraping behaviors that amplify the phenomenon of dandruff. The dandruff conditions of the scalp may be of the fatty type or of the dry type. The dry dandruff conditions of the scalp are more frequently manifested and are amplified during disorders of the hydration of the skin, and in particular during severe dryness of the epidermis of the scalp.

In addition, the scalp is rich in sebaceous glands. A hypersecretion of sebum, or seborrhea, can cause discomfort, sensations of discomfort, aesthetic disorders, even skin pathology. Thus, an excessive secretion of sebum favors the appearance of a fatty dandruff condition of the scalp or fatty dandruff. The dandruff states generally respond to different local or systemic treatments. For example, various preparations comprising antimicrobial agents or keratolytic agents or keratinization regulators are commonly proposed for treating the dandruff states. In particular, anti-fungal and anti-seborrhoeic combination preparations have been proposed to treat severe fatty eye conditions. However, the effectiveness of these treatments is only suspensive and involves rigorous monitoring by the user (frequency of use and sufficient application time). However, a daily and long-term use of these treatments can lead to a phenomenon of habituation reducing their effectiveness. Habituation may be associated with a rebound phenomenon occurring at the end of treatment. The rebound phenomenon is usually manifested by hyperseborrhea or pruritus, paradoxically likely to aggravate the dandruff condition by altering the barrier function of the scalp. Furthermore, the aggressiveness of certain antidandruff active against epidermal cells or ecoflora of the scalp can also affect the barrier functions of the latter and cause worsening of the dandruff condition.

Unpleasant side effects, such as overheating or irritation, can also occur during the implementation of these treatments. These side effects can also result in poor compliance with treatments, reducing their effectiveness. In addition, most of the assets usually employed for the treatment of dandruff are often associated with an unpleasant odor also reducing the compliance of the treatment. Finally, the effectiveness of anti-dandruff treatments is often slow to develop and requires a rigorous application in the long term. This latency often leads to a failure to monitor treatment. As a result, many failures occur in the implementation of these treatments.

There remains a need for new cosmetic treatments to prevent, reduce and / or treat dandruff conditions of the scalp that are effective and have no side effects that may affect compliance. There is also a need for treatment of dandruff conditions of the scalp whose effectiveness is manifested quickly and in a prolonged manner over time. There is still a need for a treatment of dandruff condition of the scalp whose effectiveness is increased compared to existing treatments. There is also a need for treatment of scalp dandruff conditions that do not affect the ecoflora of the scalp, or even enhance the presence of a healthy ecoflora. There is also a need for a treatment of the dandruff states able to maintain or even strengthen the hydration of the scalp. There is a need for a dandruff treatment capable of maintaining or even strengthening the barrier properties of the scalp. There is a need for treatments of dandruff states that are free of the aforementioned side effects, and in particular that do not induce hyperseborrhoea, seborrheic dermatitis or pruriginous conditions. There is also a need for a treatment of the dermal states which does not induce inflammatory conditions. Finally, there remains a need for an effective, simple treatment of the dermal states which can be carried out for a prolonged or repeated period without aggravating the dandruff condition. The object of the present invention is to satisfy these needs. Thus, according to a first object, the invention relates to a cosmetic method for preventing and / or treating a dandruff condition of the scalp, said method comprising administering an effective amount of at least a first active ingredient during a first and a second consecutive period of time, said time periods forming together a sequence, and at least one second cosmetic active, topically, for a single period of time selected from the first and second period of time, said first and second cosmetic active agents being formulated in separate compositions, the first cosmetic active agent being chosen from probiotic microorganisms, one of their fractions and / or one of their metabolites, and their mixtures, and the second cosmetic active agent being chosen among anti-dandruff active ingredients. Unexpectedly, the inventors have observed that the administration over a period of time of a probiotic microorganism, in particular of the genus Lactobacillus sp., And in particular Lactobacillus paracasei, in particular orally, with a dandruff active agent topically, in particular the pyrithione zinc, this administration being preceded or followed, and in particular followed by the administration, over another period of time, of the probiotic microorganism, in the absence of the anti-dandruff active, made it possible to effectively reduce the dandruff conditions of the scalp without evidence of side effects, such as pruriginous conditions, seborrheic dermatitis or inflammatory conditions. The effectiveness of this treatment is manifested more rapidly, and more intense, compared to the isolated use of these cosmetic active ingredients. Also, the administration over a period of time of a probiotic microorganism, especially orally, with a topical antidandruff active agent, another probiotic microorganism, this administration being preceded or followed by the administration on another time period of the first probiotic microorganism in the absence of the antidandruff active accelerates the implementation of beneficial effects of dandruff treatment and increase or even increase the intensity of effects.

In particular, the inventors have observed that at the end of a treatment of the invention the presence of dandruff was greatly reduced or non-existent, and that the barrier properties of the scalp were reinforced. Thus, surprisingly, the oral administration of probiotic microorganisms, in particular lactic acid probiotic microorganisms, by promoting the assimilation of nutrients in the intestinal mucosa essential for cellular metabolism, is capable of remotely preventing deleterious effects of topically applied dandruff active agents and to enhance their effectiveness, or even to generate a synergistic effect on the prevention, reduction and / or treatment of dandruff.

The surprising effect of the process according to the invention results from the implementation, for the first time by the inventors, of two treatment stages, ie a first stage comprising the administration, over a period of time, of a microorganism probiotic and an anti-dandruff active agent, the latter being administered topically, followed or preceded, in particular followed, by a second step comprising the administration, over another period of time, of the probiotic microorganism in the absence of dandruff active.

Such a sequence of steps advantageously makes it possible to substantially reduce, or even eliminate, the side effects of anti-dandruff active agents while reinforcing the beneficial effects of the probiotic microorganism on the barrier properties of the scalp. The protection and enhancement of scalp barrier properties allows a decrease in inflammatory conditions of the skin, the maintenance of a balanced barrier, its integrity and the preservation of a balanced ecoflora. The scalp is then less irritated and pruriginous, less fragile and more hydrated, and the dandruff states are reduced. Such a sequence of steps also makes it possible to accelerate the occurrence of the efficacy of the anti-dandruff treatment and to amplify the intensity of these beneficial effects. Administration of a probiotic microorganism alone for the maintenance or improvement of skin condition or fur of animals (WO 01/17365), or, where appropriate, in combination with topical administration of an adjunct cosmetic active to improve the appearance of cutaneous tissues (WO 2006/104730) has been proposed. For the purposes of the present invention, it is intended to prevent the total elimination or partial reduction of the risk of manifestation of a given phenomenon, i.e. in the present invention the presence of films. The partial decrease implies that the risk remains but to a lesser degree than before the implementation of the invention. Advantageously, a method of the invention makes it possible to reduce the period of application of anti-dandruff active agents, and the risk of secondary effects, while maintaining or even increasing their activity. A method of the invention advantageously makes it possible to accelerate the setting up of the beneficial effects of anti-dandruff treatment and to amplify its intensity. A method of the invention still advantageously allows to restore a healthy scalp, in perfect homeostasis and restore a balanced ecoflora. According to another advantage, a method according to the invention makes it possible to reduce and / or treat pruritus of the scalp consecutive to the use of irritating anti-dandruff active agents. According to another advantage, a method according to the invention promotes the hydration and the maintenance of the integrity of the scalp. According to one embodiment, the first cosmetic active agent is administered orally or topically, and in particular orally. According to yet another embodiment, preferably the second cosmetic active is administered during the first period of time. According to another embodiment, a method according to the invention may advantageously be suitable for the prevention and / or treatment of a dandruff condition of the scalp associated with dryness or xerosis of the scalp, a hyperseborrhea of the scalp, an ecoflora unbalanced, pruritus, inflammation of the scalp, or an unbalanced scalp barrier function. According to another of its aspects, the present invention relates to a cosmetic assembly comprising at least a first and a second cosmetic compositions, the first composition comprising at least an effective amount of at least one first cosmetic active, said first cosmetic active being Lactobacillus paracasei , one of its fractions and / or one of its metabolites, and the second composition comprising at least an effective amount of at least one second cosmetic active agent selected from anti-dandruff active agents and being administered topically.

According to another of its aspects, the subject of the invention is a cosmetic use of at least an effective amount of at least a first and a second cosmetic active agent, said first cosmetic active being Lactobacillus paracasei, one of its fractions and / or one of its metabolites, and the second active being selected from anti-dandruff active agents and being administered topically, to prevent and / or treat a dandruff condition of the scalp.

The first and second cosmetic actives are each formulated in a first and second cosmetic compositions distinct from each other. For the purposes of the present invention, the term "effective amount" means an amount sufficient to obtain the expected effect, namely, in particular, the prevention, reduction and / or treatment of the dandruff states. hairy with excessive dryness or excessive secretion of sebum, may show a dandruff condition, which, depending on the case, may be characterized by the presence of dry or oily dandruff, or even pruritus and / or inflammation of the epidermis. The dry dandruff states translate xerosis of the scalp, possibly associated with an excessively rapid renewal of its stratum corneum. Dry dandruff is usually small in size, white or gray, and spreads over the scalp and clothing that creates an unsightly visual effect.

Itching associated with dryness of the scalp can lead to erythema, pruritus, or even an inflammatory condition. Fatty dandruff is one of the forms of seborrheic dermatitis. Affected individuals have an erythematous scalp covered by large, oily and yellow scales that accumulate to form packs. They have a pruriginous scalp, and often have burning sensations on affected areas. These phenomena can be amplified by the presence of pathogenic microorganisms, including Malassezia sp .. These microorganisms with the property of releasing fatty acids from sebum can alter the barrier function of the epidermis and generate inflammatory conditions.

In the dandruff states of the scalp, the skin barrier is unbalanced, its integrity and hydration are altered and its ecoflora disturbed. The skin of the scalp is irritated and itchy, fragile, less hydrated and susceptible to infections. The implementation of a probiotic microorganism according to the invention orally with an antidandruff active topically, especially according to two periods of time as defined below, leads to restore the hydration and the ecoflora and to reduce pruritus of the scalp. This reduction results in a reduction of scalp scratching phases and the resulting alteration of the barrier function. In addition, the effectiveness of the treatment is significantly improved and is developing much faster. The skin is less irritated and less pruriginous and the presence of dandruff is reduced or eliminated.

The uses, processes and compositions according to the invention thus prove to be particularly effective: to prevent and / or treat the disorders, particularly aesthetic, of the scalp associated with excessive dryness, even xerosis, to prevent and / or or treat disorders, particularly aesthetic, of the scalp associated with excessive excretion and / or secretion of sebum, - to prevent and / or treat the dandruff states, whether dry or greasy, of the scalp, - to improve and / or restore the antimicrobial defenses of the dry or oily scalp, - to improve the comfort of the skins and the scalp, - to improve the hygiene and / or the care of the scalp, - to confer a feeling of well-being to the scalp, - to preserve and / or enhance the integrity of the barrier functions of the scalp skin, - to maintain and / or restore the biomechanical properties of the scalp, - to restore a scalp o Balanced flora of the scalp, for preventing and / or treating pruritic and / or seborrheic dermatitis associated with the dandruff states of the scalp, and for preventing and / or treating the inflammatory conditions associated with the dandruff states of the scalp.

Method A method according to the invention comprises at least two periods of time, consecutive to each other, and together forming a sequence called processing sequence. A method according to the invention comprises at least a first treatment sequence, or even a succession of several sequences, for example at least 2, 3 or 4 consecutive treatment sequences.

A processing sequence can therefore be repeated so as to obtain a succession of first and second periods of time.

Advantageously, a method of the invention comprises a repeated sequence at least once, in particular at least twice, and preferably at least three times. Alternatively, the succession of the treatment sequences may comprise between each sequence a stop treatment phase, varying from a few days, for example 1, 2, 3, 4 or 5 days or a few weeks 1, 2, 3 or 4 weeks . The first and second periods of time may range from a few days, for example 2, 3, 4, 5, 6 or 7 days to one to a few weeks, for example 2, 3, 4, 5 or 6 weeks. According to one embodiment, the two periods of time may each vary, independently of one another, from one week to six weeks, preferably from two to five weeks, and preferably from three to four weeks. According to one embodiment, the first and second periods of time may be of different duration. For example, the first period of time may be shorter than the second, or conversely the second may be shorter than the first period of time. According to another embodiment, the first period of time is equal to the second period of time. The administration of the assets is carried out at least once per period of time. Preferably, the periods of time can be divided into units of time, in particular of equal duration, for example in day or week. In such an embodiment, the administration of the assets is performed at least once per unit of time, for example at least once a day. As indicated above, the first cosmetic active agent is administered during the two periods of time, while the second cosmetic active agent is administered only during a single period of time chosen between the first and the second period of time. Advantageously, the second cosmetic active agent can be administered during the first period of time. Thus, according to a preferred embodiment of the invention, a method of the invention may comprise a first period of time comprising the administration of the first and second cosmetic actives, said first period of time being followed consecutively by a second period. of time comprising the administration of the first cosmetic active in the absence of the second cosmetic active. According to yet another embodiment, a method of the invention may comprise a first period of time comprising the administration of the first cosmetic active in the absence of the second cosmetic active, said first period of time being followed consecutively by a second period of time comprising administering the first and second cosmetic actives. When the first cosmetic active agent is administered in the absence of the second cosmetic active agent for a period of time, it may be administered by any route known to those skilled in the art, especially orally or topically, and in particular by way of oral. Since the first and second cosmetic actives are formulated in separate compositions, when administered for the same period of time, they can be administered by identical or different routes of administration. In particular, the second cosmetic active agent is administered topically, and the first cosmetic active agent can be administered orally or topically, and preferably orally. When administered for the same period of time, the first and second cosmetic actives may be sequentially administered sequentially, consecutively one after the other, separately, each at a particular time in the period of time. time, or concomitantly.

In the same period of time, the first and second cosmetic active agents can be administered, indifferently, in any order, for example the first active before the second, or the second before the first active. When administered concomitantly, the topical administration of the second cosmetic active is preferably carried out in the first place so as to be in place upon oral administration of the first cosmetic active. In a preferred embodiment, the first time period is four weeks and includes administering the first and second assets once a day, and the second time period is four weeks and includes administering the first time period. active once a day, and stopping the second asset. Probiotic microorganisms For the purposes of the present invention, probiotic microorganism means a living microorganism which, when consumed in an adequate quantity, has a positive effect on the health of its host (FAO / WHO Expert Consultation Consultation on Evaluation of In particular, it can improve microbial balance in the intestinal tract. According to one variant of the invention, a microorganism according to the invention may be used in an isolated form, that is to say unmixed with one or more compound (s) likely to be associated with it. (s) in his home environment. For the purposes of the invention, the term metabolite refers to any substance derived from the metabolism of the microorganisms considered according to the invention and also having an efficacy for the treatment of the dandruff states of the scalp. For the purposes of the invention, the term "fraction" more particularly denotes a fragment of said microorganism and has an efficacy for the treatment of dandruff conditions of the scalp by analogy with said whole microorganism. According to a preferred embodiment, the metabolites and / or the probiotic microorganism fractions that are suitable for the invention can be administered in the form of a lysate. A lysate in the sense of the invention commonly refers to a material obtained from the destruction or dissolution of biological cells by a phenomenon called cell lysis thereby causing the release of intracellular biological constituents naturally contained in the cells of the microorganism in question. For the purposes of the present invention, the term lysate is used interchangeably to designate the entirety of the lysate obtained by lysis of the microorganism concerned or only a fraction thereof. The lysate used is therefore formed in all or part of the intracellular biological constituents and constituents of the cell walls and membranes. Advantageously, a lysate used for the invention may be the entire lysate obtained by lysis of the microorganism concerned.

This cell lysis can be accomplished by various technologies, such as, for example, osmotic shock, thermal shock, ultrasound, or mechanical stress of the centrifugation type. More particularly, this lysate can be obtained according to the technology described in US Pat. No. 4,464,362, and in particular according to the following protocol. In particular, a lysate of the invention can be obtained by ultrasonic disintegration of a medium comprising probiotic microorganisms to release cytoplasmic fractions, cell wall fragments and products derived from metabolism. Then all components in their natural distribution are then stabilized in a weakly acidic aqueous solution. A lysate can be used in various forms, in the form of a solution or in a powder form. The microorganism (s) can be included in a composition according to the invention in living, semi-active or inactivated or dead form.

For the purposes of the invention, an inactivated or dead microorganism is a microorganism that is no longer capable of forming colonies in cultures. Dead or inactivated microorganisms may have intact or broken cell membranes. Obtaining dead or inactivated microorganisms can be carried out by any method known to those skilled in the art.

According to one embodiment, a probiotic microorganism that is suitable for the invention may be chosen from Lactobacillus sp., Bifidobacterium sp., Cocci, yeasts, sporulated bacteria, and mixtures thereof. According to one embodiment, a microorganism that is suitable for the invention is preferentially chosen from: lactic bacteria, which produce fermentation of lactic acid sugar. According to their morphology they are divided into two groups: Lactobacillus species: Lactobacillus acidophilus, amylovorus, casei, rhamnosus, brevis, crispatus, delbrueckii (subsp bulgaricus, lactis), fermentum, helveticus, gallinarum, gasseri, johnsonii, plantarum, reuteri, salivarius, alimentarius, curvatus, casei subsp. casei, sake, and Cocci: Enterococcus (faecalis, faecium), Lactococcus lactis (subsp lactis or cremoris), Leuconostoc mesenteroides subsp dextranicum, Pediococcus acidilactici, Sporolactobacillus inulinus, Streptococcus salvarius subsp. thermophilus, Streptococcus thermophilus, Staphylococcus carnosus, Staphylococcus xylosus, - bifidobacteria or Bifidobacterium species: Bifidobacterium adolescentis, animalis, bifidum, breve, lactis, longum, infantis, pseudocatenulatum, - yeasts: Saccharomyces (cerevisiae or boulardii), - the others spore-forming bacteria: Bacillus (cereus var toyo or subtilis), Bacillus coagulans, Bacillus licheniformis, Escherichia coli strain nissle, Propionibacterium freudenreichii, and mixtures thereof.

A microorganism that is suitable for the invention may be chosen especially from ascomycetes such as Saccharomyces, Yarrowia, Kluyveromyces, Torulaspora, Schizosaccharomyces pombe, Debaromyces, Candida, Pichia, Aspergillus and Penicillium, bacteria of the genus Bifidobacterium, Bacteroides, Fusobacterium, Melissococcus, Propionibacterium. , Enterococcus, Lactococcus, Staphylococcus, Peptostrepococcus, Bacillus, Pediococcus, Micrococcus, Leuconostoc, Weissella, Aerococcus, Oenococcus and Lactobacillus, and mixtures thereof. As another example of probiotic microorganisms that are suitable for the invention, mention may be made of Bifidobacterium adolescentis, Bifidobacterium animalis, Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium lactis, Bifidobacterium longum, Bifidobacterium infantis, Bifidobacterium pseudocatenulatum and Lactobacillus acidophilus NCFB 1748; Lactobacillus amylovorus, Lactobacillus casei (Shirota), Lactobacillus rhamnosus strain GG, Lactobacillus brevis, Lactobacillus crispatus, bulgaricus, Lactobacillus delbrueckii subsp., Lactis, Lactobacillus fermentum, Lactobacillus helveticus, Lactobacillus gallinarum, Lactobacillus gasseri, Lactobacillus johnsonii CNCM I-1225, Lactobacillus plantarum , Lactobacillus reuteri, Lactobacillus salivarius, Lactobacillus alimentarius, Lactobacillus curvatus, Lactobacillus casei subsp. Casein, Lactobacillus sake, Lactococcus lactis, Enterococcus faecalis, Enterococcus faecium, Lactococcus lactis subsp lactis, Lactococcus lactis subsp cremoris, Leuconostoc mesenteroides subsp dextranicum, Pediococcus acidilactici, Sporolactobacillus inulinus, Streptococcus salvarius subsp. thermophilus, Streptococcus thermophilus, Staphylococcus carnosus, Staphylococcus xylosus, Saccharomyces cerevisiae, Saccharomyces boulardii, Bacillus cereus var toyo, Bacillus cereus var subtilis, Bacillus coagulans, Bacillus licheniformis, Escherichia coli strain nissle, Propionibacterium freudenreichii, and mixtures thereof. More particularly, it may be a probiotic microorganism selected from Lactobacillus sp., Sporolactobacillus sp., Enterococcus sp., Lactococcus sp., Bacillus sp., Streptococcus sp., Pediococcus sp., Leuconostoc sp. or Bififobacterium sp., and in particular chosen from Lactobacillus sp. and Bifidobacterium sp., and mixtures thereof. As an illustration of these probiotic microorganisms, mention may be made more particularly of Lactobacillus johnsonii, Lactobacillus reuteri, Lactobacillus rhamnosus, Lactobacillus paracasei, Lactobacillus casei, Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium animalis, Bifidobacterium lactis, Bifidobacterium infantis, Bifidobacterium adolescentis, Bifidobacterium pseudocatenulatum, and mixtures thereof. The most suitable species are Lactobacillus johnsonii, Lactobacillus paracasei, Bifidobacterium adolescentis, Bifidobacterium longum respectively deposited according to the Budapest Treaty with the Pasteur Institute (28 rue du Docteur Roux, F-75024 Paris cedex 15) on 30/06/92, 12/01/99, 15/04/99 and 15/04/99 under the following designations CNCM I-1225, CNCM I-2116, CNCM I-2168 and CNCM I-2170, and the genus Bifidobacterium lactis (Bb 12 ) (ATCC27536) or Bifidobacterium longum (BB536). The strain of Bifidobacterium lactis (ATCC27536) can be obtained from Hansen (Hansen AIS Chr., 10-12 Boege Alle, PO Box 407, DK-2970 Hoersholm, Denmark). Advantageously, a microorganism that is suitable for the invention may be a probiotic microorganism with lactic acid. According to a preferred embodiment, a probiotic microorganism 25 suitable for the invention may in particular be a microorganism of the genus Lactobacillus sp. Preferably, a microorganism of the genus Lactobacillus sp. suitable for the invention may be selected from the species Lactobacillus johnsonii, Lactobacillus reuteri, Lactobacillus paracasei, Lactobacillus casei, and mixtures thereof. According to a preferred embodiment, a microorganism suitable for the invention may be a Lactobacillus paracasei.

A microorganism that is suitable for the invention may in particular be the strain Lactobacillus paracasei ST11 deposited according to the Budapest Treaty at the Institut Pasteur (28 rue du Docteur Roux, F-75024 Paris cedex 15) on 12/01/99 under the designation CNCM I-2116, and / or a fraction thereof and / or a metabolite thereof.

According to another preferred embodiment, a probiotic microorganism that is suitable for the invention may in particular be a microorganism of the genus Bifidbacterium sp., And in particular Bifidobacterium longum, in particular Bifidobacterium longum (BB536). Advantageously, a Bifidobacterium longum can be used in the form of a lysate, in particular obtained as described above. A microorganism of the invention may be formulated in a composition in a proportion of at least 0.0001% expressed by dry weight, in particular in a proportion of 0.0001% to 20% and more particularly in a proportion of 0.001% to 15% by weight. , in particular from 0.01 to 10% by weight, and especially from 0.1% to 2% by weight relative to the total weight of the composition containing it. In general, a composition according to the invention intended to be administered orally may comprise, for living microorganisms, from 103 to 1015 cfu / g, in particular from 105 to 1015 cfu / g and more particularly from 10 to 10 μg / g of microorganisms per gram of carrier or equivalent doses calculated for inactive or dead microorganisms or for microorganism fractions or metabolites produced. In particular, in an orally administered composition, the concentration of microorganism and / or fraction and / or corresponding metabolite may be adjusted to correspond to doses (expressed as microorganism equivalent) ranging from 5 × 10 5 to 10 13 cfu / day and in particular from 108 to 1011 cfu / day. A composition for topical application according to the invention may generally comprise from 103 to 10 cfu / g, in particular from 105 to 1010 cfu / g and more particularly from 10 to 109 cfu / g of microorganisms. In the particular case of topical administration, it may be advantageous to use microorganisms in inactivated or even dead form.

The microorganism (s) can also be included as fractions of cellular components or as metabolites. The microorganism (s), metabolite (s) or fraction (s) can also be introduced in the form of a freeze-dried powder, a culture supernatant and / or the where appropriate in a concentrated form. When a composition comprises metabolites, the contents of metabolites in the compositions substantially correspond to the levels that can be produced by 103 to 1015 cfu, in particular 105 to 1015 cfu, and more particularly 10 to 1012 cfu of living microorganisms per gram. of support.

The expression of the amount of metabolites or fractions of a microorganism in CFU, or of dead microorganisms, is intended to designate the quantity of this microorganism necessary for the production of said quantity of metabolites or fractions of microorganisms.

Dandruff active agents An anti-dandruff active agent that is suitable for use in the invention is in particular a compound capable of preventing the appearance of dandruff, reducing their number and / or eliminating them completely. An anti-dandruff active agent that is suitable for the invention may, in particular, be chosen from: pyridinethione salts, in particular calcium, magnesium, barium, strontium, zinc, cadmium, tin and zirconium. The zinc salt of pyridinethione is particularly preferred. The zinc salt of pyridinethione is especially marketed under the name Omadine zinc by OLIN. The trihalogeno-carbamide of the formula: Z ~~ NHCONH ~, ~ in which Z represents a halogen atom such as chlorine or a C 1 -C 4 trihaloalkyl group such as CF 3, - triclosan represented by the formula: and Cl OH - azole compounds such as climbazole, ketoconazole, clotrinazole, econazole, isoconazole and miconazole, - antifungal polymers such as amphotericin B or nystatin, - selenium sulphides, particularly those of formula SX Se 8_x, x ranging from 1 to 7. - sulfur in its various forms such as cadmium sulphide, - allantoin, - tars of coal or wood and their derivatives, in particular oil cade - salicylic acid, - undecylenic acid, - fumaric acid, - allylamines, such as terbinafine, - ciclopirox or octopyrox, - piroctone-olamine, - clobetasol propionate or betamethasone valerate - Melaleuca oil - Thyme and catnip oil a probiotic anti-dandruff microorganism, in particular a probiotic microorganism as defined previously as a first cosmetic active agent or, hereinafter, as a third cosmetic active agent. In particular, a probiotic microorganism that is suitable as an anti-dandruff active may be a microorganism chosen from Lactobacillus paracasei, Bifidobacterium longum or Vitreoscilla filiformis, in particular formulated in the lysate state as indicated above. - and their mixtures. As preferred examples of anti-dandruff agents, there may be mentioned zinc pyridinethione, salicylic acid, selenium disulfide, thyme and mixed catnip oil, octopyrox, a probiotic microorganism and mixtures thereof. .

A composition according to the invention advantageously comprises from 0.001 to 10% by weight of anti-dandruff agent (s), preferably from 0.1 to 5% by weight, even more preferably from 0.2 to 2% by weight. , relative to the total weight of the composition.

Additional Cosmetic Active A method according to the invention may comprise, in addition to the administration of the first and second cosmetic active agents previously defined, the administration of at least one third cosmetic active agent. Advantageously, such an additional cosmetic active may be intended to exert a cosmetic effect, care or hygiene on the hair and / or the scalp, and in particular to be intended to strengthen the cutaneous barrier. A third cosmetic active agent can be administered, indifferently, during one or the other period of time previously defined, or even during the two periods of time. A third cosmetic active may be formulated together with the first and / or second cosmetic active (s) previously defined, or formulated in a separate composition. When the third cosmetic active is formulated in a composition distinct from the compositions comprising the first and second cosmetic active agents, it may be administered orally or topically. The route of administration is chosen by those skilled in the art so as to be more particularly adapted to the nature of the third cosmetic active. According to one embodiment, a third cosmetic active agent may, in particular, be chosen from a hair coloring agent, an agent preventing hair loss and / or promoting hair regrowth, a detangling agent, a shaping agent capillary, an agent for preventing and / or treating canities, an antiseborrhoeic agent, an antibiotic agent, a hormone, an anti-androgenic agent, an additional probiotic microorganism, in particular a lysate of Bifidobacterium longum or Vitreoscilla filiformis, a moisturizing agent, an antioxidant, a vitamin, and mixtures thereof. According to an alternative embodiment, a third cosmetic active agent may be a microorganism, said second microorganism, in particular of probiotic type, and / or one of its fractions, and / or one of its metabolites, distinct from said first microorganism defined as first active agent. cosmetic. For the purposes of the invention, the distinct expression of said first probiotic microorganism means that it is possible to distinguish within the same composition either two different microorganisms, or two different forms of the same microorganism. Thus, when the second microorganism is, for example, of the genus Lactobacillus sp. or Bifidobacterium sp. and corresponds to the same species as that of the invention, this second microorganism is then present in a form other than the first microorganism.

The second probiotic microorganism may be formulated in the same composition as that containing the first cosmetic active ingredient, or in the same composition as that containing the second cosmetic active ingredient, or may be formulated in a third composition distinct from the aforementioned compositions. More particularly, it may be one of the probiotic microorganisms proposed above, as a specific example of probiotic microorganisms for the first cosmetic active. This second microorganism may be chosen especially from ascomycetes such as Saccharomyces, Yarrowia, Kluyveromyces, Torulaspora, Schizosaccharomyces pombe, Debaromyces, Candida, Pichia, Aspergillus and Penicillium, bacteria of the genus Bacteroides, Fusobacterium, Melissococcus, Propionibacterium, Enterococcus, Lactococcus, Staphylococcus, Peptostrepococcus, Bacillus, Pediococcus, Micrococcus, Leuconostoc, Weissella, Aerococcus, Oenococcus, Lactobacillus, Bifidobacterium, and mixtures thereof. Particularly suitable ascomycetes for the present invention are Yarrowia lipolitica and Kluyveromyces lactis, as well as Saccharomyces cereviseae, Torulaspora, Schizosaccharamyces pombe, Candida and Pichia. More particularly, it may be a probiotic microorganism selected from Lactobacillus sp., Sporolactobacillus sp., Enterococcus sp., Lactococcus sp., Bacillus sp., Streptococcus sp., Pediococcus sp., Leuconostoc sp. or Bififobacterium sp., and in particular selected from Lactobacillus sp. and Bifidobacterium sp., and mixtures thereof. According to a particular embodiment, the second probiotic microorganism may be chosen from Lactobacillus johnsonii, Bifidobacterium adolescentis, Bifidobacterium longum and Bifidobacterum lactis NCC 2818 respectively deposited according to the Budapest Treaty with the Institut Pasteur (28 rue du Docteur Roux, F-75024 Paris cedex 15) 30/06/92, 12/01/99, 15/04/99, 15/04/99, 07/06/05 under the following designations CNCM I-1225, CNCM I-2168 and CNCM I -2170 and CNCM I-3446, and the genus Bifidobacterium longum (BB536), and mixtures thereof. According to a particular embodiment, the second probiotic microorganism is of the genus Lactobacillus sp., In particular Lactobacillus johnsonii, one of its fractions and / or one of its metabolites. Preferably, it may especially be Lactobacillus johnsonii deposited according to the Budapest Treaty at the Pasteur Institute (28 rue du Docteur Roux, F-75024 Paris cedex 15) on 30/06/92, under the designation CNCM I -1225. According to another particular embodiment, the second probiotic microorganism may be a probiotic microorganism of the genus Bifidbacterium sp., And in particular Bifidobacterium longum, in particular Bifidobacterium longum (BB536). The second probiotic microorganism may advantageously be used in the form of a lysate, in particular obtained as described above. In particular, the second probiotic microorganism may be a Bifidobacterium longum lysate. According to yet another embodiment, an additional microorganism suitable for the invention may be selected from non-photosynthetic filamentous bacteria and / or a fraction thereof and / or a metabolite thereof. These bacteria can also be advantageously formulated as a lysate. Illustrative of these bacteria include non-synthetic filamentous bacteria as defined by Bergey's Manual of Systematic Bacteriology (Vol 3, sections 22 and 23, 9th edition, 1989), among which may be mentioned bacteria belonging to the order Beggiatoales, and more particularly the bacteria belonging to the genus Beggiatoa, Vitreoscilla, Flexithrix or Leucothrix. Among the usable bacteria, there may be mentioned, for example, Vitreoscilla filiformis (ATCC 15551), Vitreoscilla beggiatoides (ATTC 43181), Beggiatoa alba (ATCC 33555), Flexithrix dorotheae (ATCC 23163), Leucothrix mucor (ATCC 25107) and Sphaerotilus ( ATCC 13338). A third cosmetic active agent may also be chosen from: anti-seborrhoeic agents such as certain sulfur amino acids, 13-cis retinoic acid, cyproterone acetate, agents preventing hair loss and / or promoting regrows active hair, such as nicotinic acid esters, especially including tocopherol nicotinate, benzyl nicotinate and C1-C6 alkyl nicotinates, such as methyl or hexyl nicotinates; pyrimidine derivatives, such as 2,4-diamino 6-piperidinopyrimidine 3-oxide or "Minoxidil" described in US Patents 4,139,619 and 4,596,812; "Aminexil" or 2,4-diaminopyrimidine-3-oxide described in WO 96/09048; agents both lipoxygenase inhibitors and cyclooxygenase inducers, or hair-promoting cyclooxygenase-inducing agents such as those described in European Patent Application EP 0 648 488; antibiotic agents such as macrolides, pyranosides and tetracyclines, and in particular erythromycin; hormones, such as estriol or analogues, or thyroxine and its salts; anti-androgenic agents, such as oxendolone, spironolactone, diethylstilbestrol and flutamide; hair-coloring agents, detangling agents, hair-forming agents, agents for preventing and / or treating canities, or mixtures thereof.

As the third cosmetic active agent that may be mentioned, there may be mentioned vitamins, such as vitamins A, B3, B5, B6, B8, C, D, E, or PP; antioxidants, such as curcuminoids, carotenoids, polyphenol and mineral compounds; sugars; amino acids; sulfur amino acids; polyunsaturated fatty acids 3 and 6; taurine and phytosterols. In particular, it is possible to use an antioxidant complex comprising vitamins C and E, and at least one carotenoid, in particular a carotenoid chosen from (3-carotene, lycopene, astaxanthin, zeaxanthin and lutein, flavonoids such as catechins, proanthocyanidines, anthocyanins, ubiquinones, coffee extracts containing polyphenols and / or diterpenes, chicory extracts, ginkgo biloba extracts, proanthocyanidin-rich grape extracts, pepper extracts , soy extracts, other sources of flavonoids with antioxidant properties, fatty acids, prebiotics, taurine, resveratrol, amino acids of selenium, precursors of glutathione.

Among the flavonoids, catechins and OPCs (procyanidolic oligomers) are preferably chosen. It can also be at least one prebiotic or a mixture of prebiotics. More particularly, these prebiotics can be chosen from oligosaccharides, produced from glucose, galactose, xylose, maltose, sucrose, lactose, starch, xylan, hemicellulose, inulin, acacia-type gums, for example, or of their mixtures. More particularly, the oligosaccharide comprises at least one fructooligosaccharide. More particularly, this prebiotic may comprise a mixture of fructo-oligosaccharide and inulin.

In the topical dosage forms, proteins or protein hydrolysates, amino acids, and especially C2 to C10 polyols such as glycerin, sorbitol, butylene glycol and polyethylene glycol, urea allantoin, sugars and sugar derivatives, water-soluble vitamins, starch, bacterial or plant extracts such as Aloe Vera.

With regard to lipophilic active agents, it is possible to use retinol (vitamin A) and its derivatives, tocopherol (vitamin E) and its derivatives, ceramides, essential oils and unsaponifiables (tocotrienol, sesamin, gamma oryzanol, phytosterols, squalens, waxes, terpenes). As additional active ingredients in an oral dosage form, all commonly used and / or authorized ingredients may also be considered. By way of illustration, mention may be made of vitamins, minerals, essential lipids, trace elements, polyphenols, flavonoids, phytoestrogens, antioxidants such as lipoic acid and coenzyme Q10, carotenoids, prebiotics, proteins and amino acids, mono- and polysaccharides, amino-sugars, phytosterols and triterpene alcohols of vegetable origin. These are, in particular, vitamins A, C, D, E, PP and group B. Of the carotenoids, beta-carotene, lycopene, lutein, zeazanthin and astaxanthin are preferably selected. . The minerals and trace elements particularly used are zinc, calcium, magnesium, copper, iron, iodine, manganese, selenium, chromium (III). Among the polyphenol compounds, polyphenols of grape, tea, olive, cocoa, coffee, apple, blueberry, elderberry, strawberry, cranberry, and onion are also particularly preferred. Preferably, among the phytoestrogens, isoflavones are retained in the free or glycosylated form, such as genistein, daidzein, glycitein or lignans, in particular those of flax and schizandra chinensis. Amino acids or peptides and proteins containing them, such as taurine, threonine, cysteine, tryptophan, methionine. The lipids preferably belong to the group of oils containing mono and polyunsaturated fatty acids such as oleic, linoleic, alpha-linolenic, gamma-linolenic, stearidonic, long-chain omega-3 fatty acids such as EPA and DHA, conjugated fatty acids derived from plants or animals such as CLA (Conjugated Linoleic Acid). Thus, a composition intended for oral administration may further comprise at least one nutritional active agent chosen from lycopene, vitamin C, vitamin E and polyphenol compounds. An oral composition of the invention may comprise other nutritional active ingredients chosen from: - anti-aging nutritional active ingredients, such as food antioxidants, nutrients with anti-radical properties and co-factors of endogenous antioxidant enzymes, vitamins A, C, E, carotenoids, xantophyls, isoflavones, certain minerals such as zinc, copper, magnesium, selenium, lipoic acid, coenzyme Q10, superoxide dismutase (SOD) or taurine. Antiaging agents that may be mentioned include unsaponifiable fractions extracted from plant-derived lipids, aloe vera, native or hydrolyzed marine collagen, vegetable or marine oils rich in omega-3 fatty acids, omega-6 fatty acids (including gamma-linolenic acid), - the photoprotective nutritional assets such as: antioxidants and antiradicals: vitamins A, C, E, carotenoids, xantophyls, certain minerals such as zinc, copper, magnesium, selenium, coenzyme Q10, superoxide dismutase (SOD), - nutritional ingredients with moisturizing or immunomodulatory properties such as polypodium leucotomos extract, vegetable or marine oils rich in omega-3 fatty acids, omega -6, including gamma-linolenic acid.

A set according to the invention comprises at least a first and a second cosmetic compositions, the first composition comprising at least an effective amount of at least one first cosmetic active agent, said first cosmetic active being Lactobacillus paracasei, one of its fractions and or one of its metabolites, and the second composition comprising at least one effective amount of at least one second cosmetic active agent selected from anti-dandruff active agents and being administered topically. According to one embodiment, an assembly according to the invention may comprise, in addition, at least one third composition comprising at least an effective amount of at least one third cosmetic active agent, in particular as defined above. Such a third composition may be administered orally or topically. The compositions that are suitable for the process according to the invention may be in any galenic form normally available for the chosen mode of administration. The support may be of a different nature depending on the type of composition considered. More particularly, compositions for external topical administration may be aqueous, hydroalcoholic or oily solutions, solutions or dispersions of the lotion or serum type, emulsions of liquid or semi-solid consistency. liquid of the milk type, obtained by dispersion of a fatty phase in an aqueous phase (O / W) or conversely (W / O), or suspensions or emulsions, of soft, semi-solid or solid consistency, of the cream type, aqueous or anhydrous gel, microemulsions, microcapsules, microparticles, or vesicular dispersions of ionic and / or nonionic type. These compositions are prepared according to the usual methods.

These compositions may include creams for cleaning, protection, treatment or care of lotions, gels or foams for the care of the skin, such as cleaning or disinfecting lotions, bath compositions or deodorant compositions.

The compositions according to the invention may also consist of solid preparations constituting soaps or cleaning bars. They can also be used for the scalp in the form of solutions, creams, gels, emulsions, foams or in the form of aerosol compositions also containing a propellant under pressure.

A topical composition according to the invention, in particular a second composition, can advantageously be formulated in any pharmaceutical form suitable for hair care, in particular in the form of a hair lotion, a shampoo, in particular an anti-dandruff, an after-treatment. shampoo, detangler, hair cream or gel, hairspray, styling lotion, treatment lotion, dyeing composition (in particular oxidation ) optionally in the form of a coloring shampoo, a restructuring hair lotion, a permanent composition, a lotion or an anti-hair loss gel, a pest control shampoo, or a treating shampoo, especially anti-hair conditioner. seborrheic, scalp care product including anti-irritant, anti-aging, restructuring, or blood circulation activator.

When a composition of the invention is an emulsion, the proportion of the fatty phase can range from 5 to 80% by weight, and preferably from 10 to 50% by weight relative to the total weight of the composition. The oils, emulsifiers and coemulsifiers used in the composition in emulsion form are chosen from those conventionally used in the cosmetics and / or dermatological field.

The emulsifier and the coemulsifier may be present in the composition in a proportion ranging from 0.3 to 30% by weight, and preferably from 0.5 to 20% by weight relative to the total weight of the composition. When the composition of the invention is a solution or an oily gel, the fatty phase may represent more than 90% of the total weight of the composition.

In known manner, the dosage forms dedicated to topical administration may also contain adjuvants which are usual in the cosmetic, pharmaceutical and / or dermatological field, such as hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic active agents, preservatives, antioxidants, solvents, perfumes, fillers, filters, odor absorbers and dyestuffs. The amounts of these various adjuvants are those conventionally used in the field under consideration, and for example from 0.01 to 20% of the total weight of the composition. These adjuvants, depending on their nature, can be introduced into the fatty phase and / or into the aqueous phase. Fats which can be used in the invention include mineral oils such as, for example, hydrogenated polyisobutene and petrolatum oil, vegetable oils such as, for example, a liquid fraction of shea butter, sunflower oil and apricot kernels, animal oils such as perhydrosqualene, synthetic oils including Purcellin oil, isopropyl myristate and ethyl hexyl palmitate, unsaturated fatty acids and fluorinated oils, for example perfluoropolyethers. It is also possible to use fatty alcohols, fatty acids such as, for example, stearic acid and, for example, waxes such as paraffin wax, carnauba wax and beeswax. It is also possible to use silicone compounds such as silicone oils and, for example, cyclomethicone and dimethicone, waxes, resins and silicone gums. As emulsifiers that can be used in the invention, mention may be made, for example, of glycerol stearate, polysorbate 60, the cetylstearyl alcohol / cetylstearyl alcohol mixture oxyethylenated with 33 moles of ethylene oxide sold under the name Sinnowax AO by Henkel, the PEG-6 / PEG-32 / glycol stearate mixture sold under the name Tefose 63 by Gattefosse, PPG-3 myristyl ether, silicone emulsifiers such as cetyldimethicone copolyol and sorbitan mono- or tristearate, stearate; PEG-40, oxyethylenated sorbitan monostearate (200E).

As solvents that can be used in the invention, mention may be made of lower alcohols, in particular ethanol and isopropanol, and propylene glycol. The composition of the invention may also advantageously contain a thermal and / or mineral water, in particular chosen from Vittel water, the waters of the Vichy basin and Roche Posay water.

As hydrophilic gelling agents, mention may be made of carboxylic polymers such as carbomer, acrylic copolymers such as copolymers of acrylates / alkyl acrylates, polyacrylamides and in particular the polyacrylamide mixture, C13-14-Isoparaffin and Laureth-7 sold under the name Sepigel 305 by the company SEPPIC, polysaccharides such as cellulose derivatives such as hydroxyalkylcelluloses and in particular hydroxypropylcellulose and hydroxyethylcellulose, natural gums such as guar, carob and xanthan and clays. As lipophilic gelling agents, mention may be made of modified clays such as bentones, metal salts of fatty acids such as aluminum stearates and hydrophobic silica, or else ethylcellulose and polyethylene.

In the case of a composition according to the invention for oral administration, the use of an ingestible support is preferred. The unmanageable support may be of various nature depending on the type of composition considered. Particularly suitable as food or pharmaceutical carriers are tablets or lozenges, oral supplements in dry form and oral supplements in liquid form. For example, they may be food supplements, the formulation of which may be carried out by the usual methods for producing, in particular, dragees, capsules, gels, emulsions, tablets, capsules and hydrogels allowing controlled release. In particular, a microorganism according to the invention can be incorporated in all forms of food supplements or fortified foods, for example food bars or powders, compacted or not. The powders can be diluted in water, soda, dairy products or soy derivatives, or incorporated into food bars. A microorganism of the invention, one of its fractions and / or one of its metabolites, may be furthermore formulated with the excipients and components customary for such oral compositions or food supplements, namely in particular fatty components and and / or aqueous, humectants, thickeners, preservatives, texture, flavor and / or coating agents, antioxidants, preservatives and dyes customary in the field of food.

The formulating agents and excipients for oral composition, and especially for food supplements, are known in the art and are not the subject of a detailed description here. Milk, yoghurt, cheese, fermented milks, fermented milk products, ice cream, cereal-based products or fermented cereal products, powders, milk-based formulas, formulas for children and infants, confectionery-type foods, chocolate, cereals, especially pet food, tablets, capsules or tablets, suspensions of liquid bacteria, oral supplements in dry form and oral supplements in liquid form. According to one embodiment, a composition according to the invention administered orally, in particular a first composition, can be formulated in the form of dragees, capsules, gels, emulsions, tablets, capsules, hydrogels, food bars, powders, compacted or not, suspensions or liquid solutions, confectionery, fermented milks, fermented cheeses, chewing gum, toothpaste or spray solutions.

In the following description and examples, unless otherwise stated, percentages are percentages by weight and ranges of values in the form between ... and ... include the specified lower and upper bounds. The ingredients are mixed, before they are shaped, in the order and under conditions easily determined by those skilled in the art. The content and the nature of the ingredients used in the compositions of the invention are adjusted by those skilled in the art so as not to substantially affect the properties required for the compositions of the invention.

The following examples are presented by way of illustration and not limitation of the scope of the invention. EXAMPLES Example 1 First composition Formulation of dragée type Active ingredients mg / tablet Lactobacillus paracasei ST11 109 cfu Lactobacillus johnsonii 109 cfu Excipient of the core of the dragee Microcrystalline Cellulose 70 Encompress ™ 60 Magnesium Stearate 3 Anhydrous Colloidal Silica 1 Coating Agent Shellac 5 Talc 61 Sucrose 250 Polyvinylidene 6 Titanium Dioxide 0.3 Coloring Agent 5 This type of sugar can be taken 1 to 3 times per day. day.

Second composition Topical formula% by weight Acrylates / C10-30 ALKYL acrylate Crosspolymer 0.20% Propylene glycol 1.00% Sodium Laureth sulfate (3% on 28%) 45.00 20 Dimethicone PEG-7 avocadoate 0.30% Pyridinethione zinc 0.40% Tri-isopropanolamine 0.25% Deionized water qs 100%

Example 2 First composition Lotion for the scalp% by weight Lactobacillus paracasei powder ST11 5.00 2910 Antioxidant 0.05 Isopropanol 40.0 Preservative 0.30 Water qs 100% Second composition Anti-dandruff shampoo% by weight Acrylates / C10 -30 ALKYL acrylate Crosspolymer 0.20% Propylene glycol 1.00% Sodium Laureth sulfate (3mole at 28%) 45.00 Dimethicone PEG-7 avocadoate 0.30% zinc pyridinethione 0.40% Tri-isopropanolamine 0.25% Deionized water qs 100% Example 3 First composition Cream for the care of the scalp% by weight Arachidyl behenyl alcohol / arachidylglusoside 3.0% Isohexadecane 7.0% Lactobacillus paracasei powder ST11 5.00% Glycerin 2.0% Vitreoscilla extract filiformis 3.0 BHT 0.05 POB methyl 0.1 POB propyl 0.05 Water qs 100%

Second composition Anti-dandruff lotion% by weight Acrylates / C10-30 ALKYL acrylate Crosspolymer 0.20% Propylene glycol 1.00% Ethanol 60% Dimethicone PEG-7 avocadoate 0.30% Octopyrox 1.00% Tri-isopropanolamine 0.25% Water deionized qs 100%

Example 4 First composition Lotion for treating the scalp% by weight Lysate of Bifidobacterium longum 5.00 ** Magnesium gluconate 3.00 Calcium lactate 2.00 Antioxidant 0.05 Isopropanol 40.0 Preservative 0.30

Second composition Anti-dandruff shampoo% by weight Acrylates / C10-30 ALKYL acrylate Crosspolymer 0.20% Propylene glycol 1.00% Sodium Laureth sulfate (3mo at 28%) 45.00 Dimethicone PEG-7 avocadoate 0.30% Thyme oil and mixed catnip 1.00% zinc pyridinethione 20% Tri-isopropanolamine 0.25% Deionized water qs 100%

Example 5 Efficiency Study Protocol A set comprising a first oral composition based on probiotic microorganism (A) and a second topical composition based on zinc pyridinethione (B) was tested for its effectiveness vis-à-vis the dandruff condition of the scalp with regard to the administration of the compositions (A) or (B) alone. The compositions are of the following formulation: A: 1x109 cfu / g Lactobacillus paracasei ST11 NCC 2461 (CNCM I-2116) B: zinc shampoo of pyridinethione 1% The treatment consists of administering the composition (A) as a single dose daily orally and topically the composition (B) for four weeks and then the composition (A) alone for four weeks. In comparison, composition (A) is administered alone orally or composition (B) is administered alone topically for eight weeks. This study was conducted in 99 adult male subjects between the ages of 18 and 60 who were identified following a clinical assessment of their moderate to severe dermal condition with scores greater than or equal to 3 (on a scale of 0 to 4) in the presence of adherent scales on at least two quarters of the head, and their erythema of the scalp. In the clinical evaluation, the presence of an erythema was also taken into account. The 99 subjects were divided into three parallel groups of 33 subjects, with one group receiving the compositions (A) and (B) and then the composition (A) alone, one group receiving the composition (A) alone and one group receiving the composition (B) alone. The effects of an assembly and a method of the invention were tested and evaluated by comparison of the three groups on J1, J15, J29, J43, J57 through clinical evaluations carried out on the following parameters: free films, adherent scales and erythema, and the overall score was calculated. These evaluations were performed by qualified dermatologists according to the techniques usually employed in the field.

Clinical evaluation of the dandruff condition of the scalp (scores) At each visit, the dandruff condition, free films and adherent scales, was scored for each item by the investigator using a scale of 0-4 on each of the quarters as follows: Absent 1 Very light 2 Light 3 Moderate 4 Severe

The sum of the head quarter scores for free and adherent dandruff was calculated (thus the scores for each of the two items could be between 0 and 16).

Clinical evaluation of erythema of the scalp At each visit, erythema of the scalp was scored by the investigator using a scale of 0 - 4 on each of the quarters of the head as follows: 0 Absent 1 Very light 2 Light 3 Moderate 4 Severe

The sum of the scores of the quarter-heads was calculated (thus the scores could be between 0 and 16).

Overall clinical score (dandruff / erythema scores) The overall clinical score is calculated by summing the scores of free, adherent and erythema dandruff.

The scores can be between 0 and 48. Thus scores that go from 13 to 30 9 are interesting clinically, since a score of 9 corresponds to the score generally found in non-dandruff subjects (score of 3 for each item) .

Results The results, expressed in total clinical score (TSS) corresponding to the score of free films and adherent films and erythema show a significant improvement, from the first weeks of treatment, the dandruff state and the erythema of the scalp in subjects treated with the set (A) + (B) and according to the method of the invention compared to subjects receiving the composition (A) or (B) alone. In particular, the effectiveness of dandruff treatment is manifested from the first days of treatment and continues throughout the treatment with increased intensity leading to a significantly improved clinical score. On the other hand, the administration of probiotics alone results in a clinical effect which manifests itself essentially towards the last weeks of treatment, whereas the administration of the anti-dandruff active alone has a visible effect at the beginning of treatment. treatment but which eventually runs out quickly. 15

Claims (21)

REVENDICATIONS1. A cosmetic method for the prevention and / or treatment of a dandruff condition of the scalp, said method comprising administering an effective amount of at least a first cosmetic active agent for a first and a second consecutive period of time, said time periods together forming a sequence, and at least one second cosmetic active, topically, for a single time period selected from the first and second time period, said first and second cosmetic actives being formulated into compositions distinct, the first cosmetic active being selected from probiotic microorganisms, a fraction and / or one of their metabolites, and mixtures thereof, and the second cosmetic active being selected from anti-dandruff active. 2. Method according to the preceding claim, wherein said first cosmetic active agent is administered orally or topically, and in particular orally. 3. Method according to one of claims 1 or 2, wherein the second cosmetic active is administered during the first period of time. The method according to any one of the preceding claims, wherein said sequence is repeated at least once, in particular at least twice and preferably at least three times. 5. Method according to any one of the preceding claims, wherein the first and second time periods each vary, independently of one another, from one to six weeks, preferably from two to five weeks, and preferably from three to four weeks. A method according to any one of the preceding claims wherein the dandruff condition of the scalp is associated with dry scalp, hyperseborrhea of the scalp, imbalanced ecoflora, pruritus, inflammation of the scalp, or an unbalanced scalp barrier function. 7. Process according to any one of the preceding claims, in which the first cosmetic active agent is chosen from Lactobacillus sp., Bifidobacterium sp., Cocci, yeasts, sporulated bacteria, and mixtures thereof. 8. A method according to any one of the preceding claims, wherein the first cosmetic active is a probiotic microorganism selected from Lactobacillus, Sporolactobacillus sp., Enterococcus sp., Lactococcus sp., Bacillus sp., Streptococcus sp., Pediococcus sp. , Leuconostoc sp. or Bififobacterium sp., and in particular chosen from Lactobacillus sp. and Bifidobacterium sp., and mixtures thereof. 9. Process according to any one of the preceding claims, in which the first cosmetic active agent is Lactobacillus paracasei, and in particular Lactobacillus paracasei CNCM I-2116. 10. Process according to any one of the preceding claims, in which the first cosmetic active agent is used in a proportion of from 0.0001 to 20% by weight, in particular from 0.001 to 15%, and more particularly from 0.01 to 10% by weight, and especially from 0.1 to 2% by weight relative to the total weight of the composition containing it. 11. Process according to any one of the preceding claims, in which the second cosmetic active agent is chosen from pyridinethione salts, trihalocarbamides of formula: ## STR1 ## in which Z represents a halogen atom such as chlorine or a C1-C4 trihaloalkyl group such as CF3, triclosan, azole compounds, antifungal polymers, selenium sulfides, sulfur in its various forms, allantoin, coal or wood tars and their derivatives, salicylic acid, undecylenic acid, fumaric acid, allylamines and mixtures thereof, ciclopirox, octopyrox, piroctone-olamine, clobetasol propionate, betamethasone valerate, Melaleuca oil, oil thyme and mixed catnip, a probiotic microorganism, and mixtures thereof. 12. Process according to any one of the preceding claims, in which the second cosmetic active agent is chosen from pyridinethione zinc, salicylic acid, selenium disulphide, thyme and mixed catnip oil, octopyrox, a probiotic microorganism, and mixtures thereof. 13. Process according to any one of the preceding claims, in which the second active ingredient is used in a proportion of 0.001 to 10% by weight, preferably 0.1 to 5% by weight, even more preferably 0.2% by weight. at 2% by weight, relative to the total weight of the composition. 14. Process according to any one of the preceding claims, comprising the administration of at least one third cosmetic active agent, chosen in particular from a hair dyeing agent, an agent preventing hair loss and / or promoting hair regrowth, a detangling agent, a hair shaping agent, an agent for preventing and / or treating canities, an anti-seborrhoeic agent, an antibiotic agent, a hormone, an anti-androgenic agent, an additional probiotic microorganism, in particular particularly a lysate of Bifidobacterium longum or Vitreoscilla filiformis, a moisturizing agent, an antioxidant, a vitamin, and mixtures thereof. 15. The method according to the preceding claim, wherein the third cosmetic active is formulated with the first and / or second cosmetic active (s) and / or in a separate composition. 16. Cosmetic assembly comprising at least a first and a second cosmetic composition, the first composition comprising at least an effective amount of at least one first cosmetic active agent, said first cosmetic active agent being Lactobacillus paracasei, one of its fractions and / or one of its metabolites, and the second composition comprising at least an effective amount of at least one second cosmetic active agent selected from anti-dandruff active agents and being administered topically. 17. An assembly according to the preceding claim, wherein the second cosmetic active agent is as defined in any one of claims 11 to 13. 18. The combination as claimed in claim 16, in which the first composition is administered orally, and is especially formulated in the form of dragees, capsules, gels, emulsions, tablets, capsules, hydrogels, food bars, powders, compacted or not, suspensions or liquid solutions, confectionery, fermented milks, fermented cheeses, chewing gum, toothpaste, spray solutions. 19. An assembly according to any one of claims 16 to 18, wherein the second composition is a hair lotion, a shampoo, a conditioner, a detangler, a cream or a hair gel, a hairspray, a polishing lotion. in folds, a treatment lotion, a dyeing composition optionally in the form of a coloring shampoo, a restructuring hair lotion, a permanent composition, a lotion or a fall-prevention gel, an antiparasitic shampoo, or an anti-seborrheic anti-shampoo, of a scalp care product, in particular anti-irritant, anti-aging, restructuring or activator of the blood circulation. 20. The assembly according to any one of claims 16 to 19, further comprising at least a third composition comprising at least an effective amount of at least one third cosmetic active agent, in particular as defined in claim 14. 21. Cosmetic use of at least an effective amount of at least first and second cosmetic active agents, said first cosmetic active being Lactobacillus paracasei, one of its fractions and / or one of its metabolites, and the second active agent being chosen from dandruff active ingredients and being administered topically to prevent and / or treat dandruff condition of the scalp.